PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32525624-0	2020	Modulating the function of ABCB1: in vitro and in vivo characterization of sitravatinib, a tyrosine kinase inhibitor.	sitravatinib	75-87	ATP binding cassette subfamily B member 1	Homo sapiens	27-32	
32525624-2	2020	In this work, we evaluated the sensitizing effect of sitravatinib, a broad-spectrum tyrosine kinase inhibitor (TKI), on ATP-binding cassette subfamily B member 1 (ABCB1)- and ATP-binding cassette subfamily C member 10 (ABCC10)-mediated MDR.	sitravatinib	53-65	ATP binding cassette subfamily B member 1	Homo sapiens	120-161	
32525624-2	2020	In this work, we evaluated the sensitizing effect of sitravatinib, a broad-spectrum tyrosine kinase inhibitor (TKI), on ATP-binding cassette subfamily B member 1 (ABCB1)- and ATP-binding cassette subfamily C member 10 (ABCC10)-mediated MDR.	sitravatinib	53-65	ATP binding cassette subfamily B member 1	Homo sapiens	163-168	
32525624-6	2020	RESULTS: Sitravatinib considerably reversed MDR mediated by ABCB1 and partially antagonized ABCC10-mediated MDR.	sitravatinib	9-21	ATP binding cassette subfamily B member 1	Homo sapiens	60-65	
32525624-7	2020	Our in silico docking simulation analysis indicated that sitravatinib strongly and stably bound to the transmembrane domain of ABCB1 human-mouse chimeric model.	sitravatinib	57-69	ATP binding cassette subfamily B member 1	Homo sapiens	127-132	
31941029-5	2020	We discovered that at submicromolar concentrations, sitravatinib re-sensitizes ABCB1- and ABCG2-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs.	sitravatinib	52-64	ATP binding cassette subfamily B member 1	Homo sapiens	79-84	
31941029-0	2020	Sitravatinib Sensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.	sitravatinib	0-12	ATP binding cassette subfamily B member 1	Homo sapiens	24-29	
31941029-4	2020	In the present study, we investigated the effect of sitravatinib, a novel multitargeted receptor tyrosine kinase inhibitor, on human ABCB1 and ABCG2 in multidrug-resistant cancer cell lines.	sitravatinib	52-64	ATP binding cassette subfamily B member 1	Homo sapiens	133-138	
31941029-6	2020	We found that sitravatinib blocks the drug efflux function of ABCB1 and ABCG2 in a concentration-dependent manner but does not significantly alter the protein expression of ABCB1 or ABCG2 in multidrug-resistant cancer cells.	sitravatinib	14-26	ATP binding cassette subfamily B member 1	Homo sapiens	62-67	
31941029-7	2020	In conclusion, we reveal a potential drug repositioning treatment option for multidrug-resistant cancers by targeting ABCB1 and ABCG2 with sitravatinib and should be further investigated in future clinical trials.	sitravatinib	139-151	ATP binding cassette subfamily B member 1	Homo sapiens	118-123